Syndax Pharmaceuticals is looking for a Senior Director, Advanced Analytics Lead
At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies.
The Role:
We are seeking a Senior Director, Advanced Analytics Lead responsible for spearheading all advanced analytics initiatives to deliver actionable insights from real-world data sources. In this role, you will leverage advanced analytics to support decision-making processes, optimize business strategies, and ensure the success of market strategies. You will also work to leverage Artificial Intelligence/Machine Learning to provide key insights/alerts to prioritize effort with HCPs across Sales and Marketing. As a team leader, you will lead a team of professionals that support the data infrastructure and analytics of the Commercial organization.
Key Responsibilities:
Team Leadership, Data Strategy, Data Analysis & Data Collection.
Stakeholder Collaboration
Compliance & Quality
Desired Experience/Education and Personal Attributes:
Location: Syndax’s corporate office is in New York, NY.
Syndax offers a total compensation and rewards package that is among the most competitive in the industry. Base pay is just one element of our package and is determined within a range based on several factors including market data, experience, qualifications, demonstrated skills, relevant education or training, travel requirements and internal equity. Our overall package also includes an equity offering, annual target bonuses, and an outstanding benefits program. The anticipated annualized salary range for this role is $270,000 - $289,000.
About Syndax:
Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib a highly selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment for both revumenib and Niktimvo. For more information, please visit www.syndax.com/ or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Pharmaceuticals is an equal opportunity employer and will not discriminate against any employee or applicant on the basis of age, color, disability, gender, national origin, race, religion, sexual orientation, veteran status, or any classification protected by federal, state, or local law.
#LI-Remote
ThinkBAC Consulting
Netflix
Profitroom
McKesson Canada
Cleveland Clinic